Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment. The vanguard industry is booming despite a host of regulatory unknowns, as practitioners educate themselves on the therapeutic potential of psilocybin—and other drugs such as cannabis and methylenedioxymethamphetamine (MDMA)—while betting on imminent federal legalization.
